Douglas, R. S. (2018). Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: A focus on proptosis. Eye (Lond).
Citação norma ChicagoDouglas, Raymond S. "Teprotumumab, an Insulin-like Growth Factor-1 Receptor Antagonist Antibody, in the Treatment of Active Thyroid Eye Disease: A Focus On Proptosis." Eye (Lond) 2018.
Citação norma MLADouglas, Raymond S. "Teprotumumab, an Insulin-like Growth Factor-1 Receptor Antagonist Antibody, in the Treatment of Active Thyroid Eye Disease: A Focus On Proptosis." Eye (Lond) 2018.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.